Table 2– Predicted number of relapses and respective drug resistance pattern in those who relapse during standardised initial treatment followed by standardised retreatment (hypothetical cohorts of 1,000 new cases in each country start initial therapy with one of two standardised regimens)
CountryInitial regimenRelapses after initial treatmentRelapses after retreatment
Patients who relapse# nPan- sensitive %Resistance %MDR-TB %Patients who relapse nPan-sensitive %Resistance %MDR-TB %
Dominican Republic2HRZE/6HE1263637272941086
2HRZE/4HR65301456262296
Peru2HRZE/6HE9660251514111078
2HRZE/4HR4455936126293
Vietnam2HRZE/6HE135346161393358
2HRZE/4HR42453025106689
UR Tanzania2HRZE/6HE83762135351946
2HRZE/4HR3380811420575
Nicaragua2HRZE/6HE88692935322642
2HRZE/4HR33771310419774
Gambia2HRZE/6HE80791834411642
2HRZE/4HR3283710323572
Kenya2HRZE/6HE86712903513811
2HRZE/4HR31831532351254
  • Cases that died while on treatment were excluded from the calculations. MDR: multidrug-resistance; TB: tuberculosis; 2HRZE: isoniazid, rifampin, pyrazinamide and ethambutol for 2 months; 6HE; isoniazid plus ethambutol for 6 months; 4HR: isoniazid plus rifampin for 4 months. #: and start retreatment; : except MDR.